Dare Bioscience, Inc. current report, 14 July 2025

Dare Bioscience, Inc. (DARE) - Form 8-K Summary

Business Context and Reporting Period

This Current Report on Form 8-K was filed on July 14, 2025, by Dare Bioscience, Inc., a Delaware corporation. The filing discloses interim results from an ongoing Phase 3 clinical trial for Ovaprene, the Company's investigational monthly, hormone-free intravaginal contraceptive (ClinicalTrials.gov ID: NCT06127199).

Key Financial Metrics

The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on clinical trial progress and does not contain financial statements or operational financial data.

Material Changes and Clinical Trial Updates

  • Interim Analysis Date: July 11, 2025.
  • DSMB Recommendation: The Data Safety Monitoring Board recommended the study continue without modification.
  • Safety Findings: No new safety or tolerability concerns were identified. No serious safety concerns were reported.
  • Pregnancy Rate: Approximately 9% of women treated in the study had experienced a pregnancy at the time of the interim analysis.
  • Discontinuation Rate: Approximately 17% of participants discontinued the study, primarily due to vaginal odor, which was the most commonly reported product-related adverse event.
  • Participant Feedback: Participants who completed the study reported they would be very likely or likely to use Ovaprene if available.
  • Study Status: Approximately 115 participants were ongoing or had completed the study. The target enrollment is approximately 250 participants completing approximately 12 months of use.

Outlook, Risks, and Management Commentary

Management highlighted that overall tolerability was favorable despite the discontinuation rate related to vaginal odor. The primary objective remains assessing the typical use pregnancy rate over 13 menstrual cycles (Pearl Index). Secondary objectives include assessing cumulative pregnancy rates, safety, acceptability, product fit, and vaginal health. The filing notes that the information provided is not deemed "filed" for purposes of Section 18 of the Exchange Act.

Key Facts for Investor Verification

  • Verify the clinical significance of the 9% pregnancy rate observed in the interim analysis against the target Pearl Index for market approval.
  • Assess the impact of the 17% discontinuation rate due to vaginal odor on future commercial viability and potential product reformulation needs.
  • Monitor the timeline for reaching the target enrollment of 250 participants and the final study completion date.
  • Review the full press release (Exhibit 99.1) for detailed statistical data not included in the 8-K summary text.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.